Gain Therapeutics (GANX) Change in Cash (2020 - 2026)

Gain Therapeutics' Change in Cash history runs 7 years deep, the most recent figure standing at -$4.3 million for Q1 2026.

• In Q1 2026, Change in Cash fell 226.91% year-over-year to -$4.3 million; the TTM figure through Mar 2026 stood at $7.5 million (up 575.91% YoY), while the FY2025 annual figure was $10.5 million, up 840.84% from the prior year.
• Change in Cash for Q1 2026 stood at -$4.3 million, down from $12.0 million in the prior quarter.
• The five-year high for Change in Cash was $12.0 million in Q4 2025, with the low at -$20.0 million in Q2 2022.
• The 5-year median for Change in Cash is -$1.7 million (2024), against an average of -$1.2 million.
• The sharpest annual moves came in 2022 and 2024: Change in Cash sank 483.79% in 2022, then soared 1793.79% in 2024.
• Gain Therapeutics' Change in Cash stood at -$3.6 million in 2022, then soared by 311.01% to $7.5 million in 2023, then plunged by 122.14% to -$1.7 million in 2024, then surged by 822.19% to $12.0 million in 2025, then tumbled by 135.73% to -$4.3 million in 2026.
• Business Quant data shows GANX's Change in Cash at -$4.3 million in Q1 2026, $12.0 million in Q4 2025, and $2.1 million in Q3 2025.